In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading

Virchows Archiv

Volumn 468, Issue 5, 2016, Pages 607-617

  Picanco Albuquerque C G ^a   Morais, C L ^b   Carvalho, F L F ^b   Peskoe, S B ^c   Hicks, J L ^b   Ludkovski, O ^d   Vidotto, T ^a   Fedor, H ^b   Humphreys, E ^b   Han, M ^b   Platz, E A ^b,c   De Marzo, A M ^b   Berman, D M ^b,d   Lotan, T L ^b   Squire, J A ^a,d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

Gleason upgrade; Hemizygous and homozygous genomic deletion; Prognostic biomarker assay; Tumor suppressor gene

Indexed keywords

PEROXIDASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GLEASON SCORE; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN DEPLETION; SIGNAL DETECTION; TUMOR BIOPSY; UNCERTAINTY; AGED; CHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATE TUMOR;

AGED; BIOMARKERS, TUMOR; BIOPSY, NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE;

EID: 84957655735     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-016-1904-2     Document Type: Article

References (24)

1. Verhagen PCMS, van Duijn PW, Hermans KGL et al (2006) The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 208(5):699–707. doi:10.1002/path.1929
2. Yoshimoto M, Cunha IW, Coudry a RA et al (2007) FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97(5):678–685. doi:10.1038/sj.bjc.6603924
3. Reida HM, Attard G, Ambroisine L et al (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102(4):678–684. doi:10.1038/sj.bjc.6605554
4. Krohn A, Diedler T, Burkhardt L et al (2012) Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 181(2):401–412. doi:10.1016/j.ajpath.2012.04.026
5. Burdelski C, Reiswig V, Hube-Magg C et al. (2015) Cytoplasmic accumulation of sequestosome 1 (p62) is a predictor of biochemical recurrence, rapid tumor cell proliferation and genomic instability in prostate cancer. Clin Cancer Res 1. doi:10.1158/1078-0432.CCR-14-0620.
6. Troyer DA, Jamaspishvili T, Wei W et al. (2015) A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate:n/a - n/a. doi:10.1002/pros.23003.
7. Sircar K, Yoshimoto M, Monzon FA et al (2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218(4):505–513. doi:10.1002/path.2559
8. Cuzick J, Yang ZH, Fisher G et al (2013) Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer 108(12):2582–2589. doi:10.1038/bjc.2013.248
9. Boström PJ, Bjartell AS, Catto JWF et al. (2015) Genomic predictors of outcome in prostate cancer. Eur Urol. doi:10.1016/j.eururo.2015.04.008.
10. Punnen S, Freedland SJ, Presti JC et al (2014) Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol 65(6):1171–1177. doi:10.1016/j.eururo.2013.03.058
11. Mithal P, Allott E, Gerber L et al. (2014) PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Urol.
12. Lotan TL, Carvalho FL, Peskoe SB et al (2014) PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol 28(1):1–10. doi:10.1038/modpathol.2014.85
13. Shah RB, Bentley J, Jeffrey Z, Demarzo AM (2015) Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling. Hum Pathol 46(5):698–706. doi:10.1016/j.humpath.2015.01.008
14. Yoshimoto M, Ludkovski O, Degrace D et al (2012) PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosom Cancer 51(2):149–160. doi:10.1002/gcc.20939
15. Epstein JI, Allsbrook WC, Amin MB, Egevad LL (2006) Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. In: Advances in Anatomic Pathology 13:57–59. doi:10.1097/01.pap.0000202017.78917.18.
16. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597. doi:10.1097/00005392-199910000-00103
17. Ventura RA, Martin-Subero JI, Jones M et al (2006) FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 8(2):141–151. doi:10.2353/jmoldx.2006.050083
18. Lotan TL, Gurel B, Sutcliffe S et al (2011) PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 17(20):6563–6573. doi:10.1158/1078-0432.CCR-11-1244
19. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13(5):283–296. doi:10.1038/nrm3330
20. Hoogland AM, Kweldam CF, Van Leenders GJLH (2014) Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review. Biomed Res Int 2014:1–12. doi:10.1155/2014/341324
21. Krohn A, Freudenthaler F, Harasimowicz S et al. (2014) Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Mod Pathol:1–9. doi:10.1038/modpathol.2014.70.
22. Gumuskaya B, Gurel B, Fedor H et al (2013) Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion. Prostate Cancer Prostatic Dis 16(2):209–215. doi:10.1038/pcan.2013.8
23. Yoshimoto M, Ding K, Sweet JM et al. (2013) PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol 1–13. doi:10.1038/modpathol.2012.162.
24. Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/JCO.2013.50.9984